Talquetamab plus Teclistamab in Relapsed or Refractory Multiple MyelomaYaël C. Cohen, María‐Victoria Mateos, Emma C. Scott et al.|New England Journal of Medicine|2025Cited by 96
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myelomaSuzette Girgis, Jenna D. Goldberg, Shun Xin Wang Lin et al.|Blood Advances|2022Cited by 52
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple MyelomaSuzette Girgis, Yusri Elsayed, Shun Xin Wang Lin et al.|Targeted Oncology|2022Cited by 21
Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.Suzette Girgis, Jenna D. Goldberg, Shun Xin Wang Lin et al.|Journal of Clinical Oncology|2021Cited by 5
Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma PatientsSuzette Girgis, Amarnath Sharma, Shun Xin Wang Lin et al.|Blood|2020Cited by 2